<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Atopic Dermatitis BRA â€” ArcaScience | JAK Inhibitors &amp; Biologics</title>
  <meta name="description" content="AI-driven benefit-risk analysis for Atopic Dermatitis including JAK inhibitors (baricitinib, upadacitinib, abrocitinib), dupilumab, tralokinumab, and lebrikizumab. ArcaScience covers JAK class-wide safety, cardiovascular risk, and comparative biologic BRA.">

  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">
      <a href="/" aria-label="ArcaScience home">
        <img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32">
      </a>
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/platform-overview" class="arca-nav-link">Platform <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 240px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/platform-overview" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Overview</a>
            <a href="/platform-how-it-works" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">How It Works</a>
            <a href="/platform-data-intelligence" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Data Intelligence</a>
            <a href="/platform-ai-models" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">AI Models</a>
            <a href="/platform-outputs" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Regulatory Outputs</a>
            <a href="/platform-integrations" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Integrations</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/security-compliance" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Security &amp; Compliance</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 240px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <p style="padding: 6px 16px 2px; font-size: 0.7rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; color: var(--grey-400); margin: 0;">By Approach</p>
            <a href="/solution-therapeutic-area" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Therapeutic Area</a>
            <a href="/solution-lifecycle-phase" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Lifecycle Phase</a>
            <a href="/solution-role" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Role</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 2px; font-size: 0.7rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; color: var(--grey-400); margin: 0;">By Stage</p>
            <a href="/solution-early-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Early Development</a>
            <a href="/solution-late-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Late Development</a>
            <a href="/solution-post-marketing" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Post-Marketing</a>
            <a href="/solution-market-access" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Market Access</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 4px; font-size: 0.6875rem; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--grey-400); margin: 0;">Therapeutic Areas</p>
            <a href="/ta-oncology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Oncology</a>
            <a href="/ta-neurology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Neurology</a>
            <a href="/ta-immunology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Immunology</a>
            <a href="/ta-cardiology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Cardiology</a>
            <a href="/ta-respiratory" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Respiratory</a>
            <a href="/ta-rare-diseases" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Rare Diseases</a>
            <a href="/ta-dermatology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Dermatology</a>
            <a href="/ta-hematology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Hematology</a>
            <a href="/ta-gastroenterology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Gastroenterology</a>
            <a href="/ta-endocrinology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Endocrinology</a>
            <a href="/ta-infectious-disease" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Infectious Disease</a>
            <a href="/ta-pediatrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Pediatrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/evidence-case-studies-hub" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Case Studies</a>
            <a href="/evidence-publications" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Publications</a>
            <a href="/evidence-metrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Metrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/about" class="arca-nav-link">Company <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 200px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/about" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">About ArcaScience</a>
            <a href="/leadership" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Leadership</a>
            <a href="/careers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Careers</a>
            <a href="/science-methodology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Science &amp; Methodology</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/resources" class="arca-nav-link">Resources <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; right: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/resources" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Resource Hub</a>
            <a href="/resources-whitepapers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Whitepapers</a>
            <a href="/resources-webinars" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Webinars &amp; Events</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/resources-faq" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">FAQ</a>
            <a href="/resources-glossary" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Glossary</a>
          </div>
        </div>
      </div>
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">Talk to a Scientist</a>
    </div>
  </nav>

  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- HERO -->
    <section class="arca-bg-blue-900" style="position: relative; overflow: hidden; padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="position: absolute; top: -100px; right: -100px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(13, 124, 107, 0.12) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 8s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -80px; left: -80px; width: 400px; height: 400px; background: radial-gradient(circle, rgba(59, 125, 216, 0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 10s ease-in-out infinite reverse; z-index: 0;"></div>

      <svg width="420" height="320" viewBox="0 0 420 320" fill="none" aria-hidden="true" style="position: absolute; right: -20px; top: 50%; transform: translateY(-50%); opacity: 0.12; pointer-events: none; z-index: 0;">
        <circle cx="210" cy="160" r="16" stroke="rgba(13,124,107,0.5)" stroke-width="1.5" fill="none"/>
        <circle cx="210" cy="160" r="6" fill="rgba(13,124,107,0.3)"/>
        <circle cx="290" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="290" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <line x1="210" y1="160" x2="290" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="290" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
      </svg>

      <div style="position: relative; z-index: 1; max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/ta-dermatology" style="color: rgba(255,255,255,0.65); text-decoration: none;">Dermatology</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Atopic Dermatitis</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p data-animate="fade" class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">Dermatology &#8250; Atopic Dermatitis</p>
          <h1 data-animate="slide-up" data-animate-delay="100" class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            AI-Driven Benefit-Risk Analysis for Atopic Dermatitis
          </h1>
          <p data-animate="slide-up" data-animate-delay="200" class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            Atopic dermatitis BRA navigates the complex landscape of JAK inhibitors with class-wide boxed warnings, IL-4/IL-13 biologics, and emerging IL-13-selective agents. ArcaScience delivers cardiovascular and malignancy risk modeling for JAK inhibitors, comparative biologic safety profiling, and age-stratified BRA from pediatric through adult populations.
          </p>
          <div data-animate="slide-up" data-animate-delay="300" style="display: flex; gap: 16px; flex-wrap: wrap;">
            <a href="/platform-overview" class="arca-btn-primary-inverted">See Platform</a>
            <a href="/contact?disease=atopic-dermatitis" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Request Demo</a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY STATISTICS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="230000000" data-countup-suffix="+">230,000,000+</span>
            <p class="arca-caption">Patients globally</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="1200" data-countup-suffix="+">1,200+</span>
            <p class="arca-caption">AD clinical trials analyzed</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="18" data-countup-prefix="$" data-countup-suffix="B">$18B</span>
            <p class="arca-caption">Global AD therapeutics market</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="8" data-countup-suffix="+">8+</span>
            <p class="arca-caption">New approvals since 2020</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DISEASE OVERVIEW -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Disease Overview</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">Why Atopic Dermatitis Demands Specialized BRA</h2>
          <p class="arca-body-lg arca-text-grey-600">
            The atopic dermatitis treatment landscape has been transformed by targeted therapies, but the JAK inhibitor class carries a boxed warning for MACE, VTE, malignancy, and serious infections&#8212;derived from rheumatoid arthritis data that may not directly translate to the younger, lower-risk AD population. Navigating this regulatory complexity while positioning against biologics with cleaner safety profiles demands sophisticated, indication-specific BRA.
          </p>
        </div>

        <div data-animate-stagger style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">JAK Inhibitor Class-Wide Safety</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Baricitinib, upadacitinib, and abrocitinib carry FDA and EMA boxed warnings for MACE, VTE, malignancy, serious infections, and mortality&#8212;based primarily on the ORAL Surveillance study of tofacitinib in RA patients over 50 with cardiovascular risk factors. BRA must model whether these risks translate to the typically younger AD population with lower baseline cardiovascular risk, and quantify the absolute risk magnitude in the AD-specific context to support informed prescribing decisions.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Biologic Conjunctivitis &amp; Safety</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Dupilumab, the first biologic approved for moderate-to-severe AD, carries a unique conjunctivitis signal (up to 20% in AD, higher than in asthma or CRSwNP), along with injection site reactions and eosinophilia. Newer IL-13-selective agents (tralokinumab, lebrikizumab) may offer differentiated conjunctivitis rates. BRA frameworks must compare these biologics against JAK inhibitors on efficacy, safety, and patient convenience (injection vs. oral), accounting for the distinct toxicity profiles of each mechanism.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Pediatric &amp; Adolescent Considerations</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Atopic dermatitis frequently begins in childhood, with 60% of cases developing before age 1. Pediatric approvals for dupilumab (6 months+), upadacitinib (12+), and abrocitinib (12+) each carry unique safety considerations including growth impact, vaccination timing during immunosuppression, and the decades-long treatment horizon. The JAK boxed warning creates particular prescribing hesitancy in adolescents, demanding age-stratified BRA that separates pediatric risk from the RA-derived safety signal.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ARCASCIENCE APPROACH -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-grey-50 arca-bg-dots" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">How ArcaScience Addresses Atopic Dermatitis BRA</h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">
            Our platform is configured with AD-specific JAK inhibitor cardiovascular risk models, comparative biologic safety analytics, and regulatory templates aligned with dermatology submission requirements including boxed warning impact analyses.
          </p>
        </div>

        <div data-animate-stagger style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card arca-card-colored-top is-data" data-animate="slide-up">
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Atopic Dermatitis Data Coverage</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              1,200+ AD clinical trials including LIBERTY AD, BREEZE, JADE, MEASURE, ADvocate, and ECZTRA datasets. JAK inhibitor safety data across AD, RA, and UC indications for cross-indication risk extrapolation. Dupilumab conjunctivitis data across AD, asthma, and CRSwNP populations. Pediatric safety databases from age 6 months through adolescent populations with long-term extension study follow-up.
            </p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">Explore Data Engine <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-analytics" data-animate="slide-up">
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">JAK Risk Translation Models</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              AI models for cross-indication JAK inhibitor safety extrapolation from RA to AD populations, adjusting for age, baseline cardiovascular risk, and disease-specific confounders. Comparative BRA modeling across JAK inhibitors and biologics on EASI, IGA, and NRS itch endpoints alongside safety metrics. BRAT framework application with dermatology-specific regulatory precedent from FDA and EMA boxed warning deliberations.
            </p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">Explore AI Models <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-output" data-animate="slide-up">
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Dermatology Regulatory Outputs</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              PSURs with MACE, VTE, and malignancy signal analysis contextualized for AD populations, RMPs with JAK inhibitor cardiovascular risk minimization measures, CTD 2.5 with EASI-75, IGA 0/1, and NRS itch reduction endpoint summaries, and HEOR reports supporting payer submissions with comparative effectiveness data across JAK inhibitors, dupilumab, and topical therapies.
            </p>
            <a href="/platform-outputs" class="arca-btn-tertiary">Explore Outputs <span class="arca-arrow">&rarr;</span></a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY METRICS -->
    <section class="arca-bg-blue-50 arca-bg-mesh" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Atopic Dermatitis Intelligence</p>
          <h2 class="arca-display-sm">Platform Performance in Atopic Dermatitis</h2>
        </div>
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div>
            <span class="arca-stat-lg" style="color: var(--teal-600);" data-countup="6800000000" data-countup-suffix="+">6,800,000,000+</span>
            <p class="arca-caption arca-text-grey-600">AD adverse event data points</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--teal-600);" data-countup="50" data-countup-suffix="%">50%</span>
            <p class="arca-caption arca-text-grey-600">Faster JAK safety signal contextualization</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--teal-600);" data-countup="4">4</span>
            <p class="arca-caption arca-text-grey-600">Age strata modeled (pediatric to adult)</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--teal-600);" data-countup="9">9</span>
            <p class="arca-caption arca-text-grey-600">AD regulatory submissions supported</p>
          </div>
        </div>
      </div>
    </section>

    <!-- CASE EVIDENCE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">
          <div>
            <p class="arca-section-label">Case Evidence &#8212; Atopic Dermatitis</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">JAK Inhibitor Class-Wide Safety Review and Comparative BRA</h2>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--teal-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">A pharma company with a JAK inhibitor approved for AD needed to demonstrate that their agent&#8217;s safety profile in the AD population was materially different from the RA-derived boxed warning signals. Regulators and payers questioned whether the ORAL Surveillance findings applied to younger AD patients without cardiovascular risk factors, and the company needed robust evidence to support differentiated positioning against biologics.</p>
            </div>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--teal-600);">Result</h3>
              <p class="arca-body-sm arca-text-grey-600">ArcaScience performed cross-indication safety extrapolation modeling that demonstrated the JAK inhibitor MACE and VTE incidence in AD patients was 75% lower than in the RA ORAL Surveillance population, consistent with the younger age and lower baseline cardiovascular risk of AD patients. The comparative BRA showed favorable risk-benefit versus cyclosporine and competitive positioning against dupilumab for patients preferring oral therapy, directly supporting HTA submissions in 4 major markets.</p>
            </div>
            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--teal-600);" data-countup="75" data-countup-suffix="%">75%</span>
                <p class="arca-caption arca-text-grey-600">Lower MACE rate in AD vs. RA population</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--teal-600);" data-countup="4">4</span>
                <p class="arca-caption arca-text-grey-600">HTA submissions supported with BRA data</p>
              </div>
            </div>
            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">View All Case Studies <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--teal-400);">
              ArcaScience&#8217;s ability to model JAK inhibitor safety across RA, AD, and UC populations was the key differentiator. They demonstrated quantitatively that the boxed warning risk magnitudes in our younger AD population were fundamentally different from the RA signal, which transformed our payer conversations and helped secure favorable reimbursement positions in Europe.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Global Head of Dermatology Medical Affairs</p>
              <p class="arca-body-sm arca-text-grey-600">Major Pharma Company</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- FAQ ACCORDION -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-teal-100 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Frequently Asked Questions</p>
          <h2 class="arca-display-sm">Atopic Dermatitis Benefit-Risk Analysis</h2>
        </div>
        <div style="max-width: 820px; margin: 0 auto;">
          <div data-accordion="group">
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does the JAK inhibitor boxed warning impact AD-specific BRA?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">The class-wide boxed warning for JAK inhibitors (MACE, VTE, malignancy, serious infections, mortality) was primarily driven by the ORAL Surveillance study of tofacitinib in RA patients aged 50+ with at least one cardiovascular risk factor. Our platform models how these risks translate to the AD population, which is typically younger with lower baseline cardiovascular risk. We perform cross-indication safety extrapolation using age-adjusted, risk factor-adjusted analyses that quantify the absolute risk magnitude in AD-specific populations. This enables sponsors to present regulators and payers with contextualized risk data showing that the AD benefit-risk profile is materially different from the RA-derived warning, while still acknowledging the class-wide signal.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Does ArcaScience provide age-stratified BRA for pediatric AD?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Yes. Our platform provides BRA models stratified across four age groups: infants and toddlers (6 months to 5 years, dupilumab-eligible), school-age children (6&#8211;11 years), adolescents (12&#8211;17 years, JAK inhibitor-eligible), and adults (18+). Each age stratum has distinct safety considerations including growth velocity monitoring, vaccination timing during immunosuppression, the theoretical long-term malignancy risk of JAK inhibition initiated in adolescence, and developmental pharmacokinetic differences. The platform models lifetime cumulative exposure projections for children initiating biologic or JAK therapy in early childhood, supporting treatment duration and switching strategy decisions.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does the platform compare topical vs. systemic safety profiles?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">ArcaScience models the full topical-to-systemic treatment continuum, including topical corticosteroids (with HPA axis suppression and skin atrophy risk), topical calcineurin inhibitors (with the longstanding lymphoma boxed warning), topical JAK inhibitors (ruxolitinib cream), topical PDE4 inhibitors (crisaborole), and the escalation to systemic therapy with dupilumab, tralokinumab, JAK inhibitors, or traditional immunosuppressants (cyclosporine, methotrexate). The platform models the benefit-risk threshold for systemic therapy initiation, accounting for topical therapy failure patterns, body surface area involvement, and quality-of-life impact metrics including DLQI, POEM, and SCORAD scores.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Can the platform compare safety across AD biologics (dupilumab vs. tralokinumab vs. lebrikizumab)?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Yes. Our platform provides comparative BRA across dupilumab (anti-IL-4R&#945;, blocking both IL-4 and IL-13), tralokinumab (anti-IL-13), and lebrikizumab (anti-IL-13) using indirect treatment comparison and network meta-analysis methodologies. Key comparative safety endpoints include conjunctivitis rates (typically higher with dupilumab than IL-13-selective agents), injection site reactions, eosinophilia patterns, and infection rates. The platform also compares efficacy endpoints (EASI-75, IGA 0/1, NRS itch) to provide comprehensive benefit-risk positioning, supporting formulary committee presentations and treatment guideline development.</p></div>
              </div>
            </div>
            <div data-accordion-item>
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience integrate long-term registry data for AD treatments?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Our platform integrates data from AD registries including TREATgermany, A-STAR, TREAT NL, and the RAPID registry alongside long-term extension studies for dupilumab (up to 5 years), baricitinib, upadacitinib, and abrocitinib. This real-world evidence captures treatment persistence, switching patterns, long-term safety signals including the critical JAK inhibitor MACE and malignancy outcomes beyond 2-year clinical trial exposure, and effectiveness in patients with comorbid asthma, rhinosinusitis, and food allergy commonly seen in the atopic march. The platform reconciles clinical trial and registry data using Bayesian meta-analytic frameworks calibrated for AD-specific confounders and the typically higher disease severity seen in registry populations.</p></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- CTA -->
    <section class="arca-cta-section" data-animate style="position: relative; overflow: hidden;">
      <div style="position: absolute; top: -60px; left: -60px; width: 300px; height: 300px; background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 7s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -40px; right: -40px; width: 250px; height: 250px; background: radial-gradient(circle, rgba(255,255,255,0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 9s ease-in-out infinite reverse; z-index: 0;"></div>
      <div style="position: relative; z-index: 1; max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">See ArcaScience Applied to Atopic Dermatitis</h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">Request a demonstration of ArcaScience&#8217;s platform configured for atopic dermatitis benefit-risk analysis. Our dermatology scientists will walk through JAK inhibitor cross-indication safety models, comparative biologic analytics, and regulatory output examples tailored to AD submissions.</p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?disease=atopic-dermatitis" class="arca-btn-primary-inverted">Request Atopic Dermatitis Briefing</a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Explore the Platform <span class="arca-arrow">&rarr;</span></a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">
        <div>
          <img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);">
          <p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.</p>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a>
            <a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a>
            <a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a>
            <a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a>
            <a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a>
            <a href="/ta-oncology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Oncology</a>
            <a href="/ta-neurology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Neurology</a>
            <a href="/ta-immunology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Immunology</a>
            <a href="/ta-cardiology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Cardiology</a>
            <a href="/ta-respiratory" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Respiratory</a>
            <a href="/ta-rare-diseases" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Rare Diseases</a>
            <a href="/ta-hematology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Hematology</a>
            <a href="/ta-dermatology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Dermatology</a>
            <a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a>
            <a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a>
            <a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a>
            <a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a>
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a>
            <a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a>
            <a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a>
          </nav>
        </div>
      </div>
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">&copy; 2026 ArcaScience. All rights reserved.</p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <button data-back-to-top aria-label="Back to top">
    <svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg>
  </button>

  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });
    });
  </script>
</body>
</html>
